The diagnosis of cutaneous lymphomas (CLs) in India has been difficult as the plethora of hypopigmentary disorders such as Hansen\'s disease and vitiligo mimic the most common variant of CLs, hypopigmented mycosis fungoides (MF). Paradoxically, while erythrodermic patients almost always undergo ruling out Sezary syndrome, not a single case has been reported from this population. The multitude of patients and limited biopsies performed in most outpatient departments mean that clinicians can miss out on diagnosis, given that lymphomas have been differentials more often than primary diagnosis. That trend has changed over the years in the past two decades, almost since the first case series was reported by George *et al*.\[[@ref1]\] in 1999 with 31 cases over 10 years (1990--99) at Christian Medical College, Vellore. In the year 2012, from the same center, Burad *et al*.\[[@ref2]\] published a case series of peripheral T-cell lymphomas over a 2-year study period with 61 cases of CL.

In the past 2 years, more than thirty case reports, series, or reviews have been published in Indian and international journals, a few of which will be highlighted in this discussion. A large retrospective series was published in 2011 by Doshi and Khopkar\[[@ref3]\] from Mumbai with 131/141 cases being cutaneous T-cell lymphomas (CTCLs) over 5 years. MF was most common of all CLs. Similar results are reported by Khader *et al*. from Kozhikode, Kerala, with 20/35 patients with MF in 2016 in a 6-year retrospective study.\[[@ref4]\]

A blessing in disguise is the fact that early stage of these conditions is indolent and often responds to topical steroids or phototherapy offered for suspected vitiligo. The problem of diagnosis of lymphomas in early stage has been difficult.\[[@ref5]\] Several papers in Indian journals have helped make this clear while it remains an exercise with every suspected patient.\[[@ref6][@ref7]\] In an extensive and categorical review, Charli-Joseph *et al*. have discussed when to consider lymphoma in a biopsy with atypical lymphoid infiltrates in this journal earlier in 2016 which remains one of the most exhaustive reviews on this rather difficult yet common problem.\[[@ref8]\]

In this symposium, we were privileged to have Professor Martine Bagot discuss the latest management options for CTCLs from the center that has pioneered therapy and research and even had the term "MF" coined by an ex-director of the same department, Professor Alibert, at the Hospital Saint-Louis, Paris. She is the national referral person for CLs in France and is a world leader in CLs, being on board for EORTC/ISCL consensus teams. Dr. Roberta La Selva *et al*. and her colleagues including Professor Pietro Quaglino who is the Chair for Cutaneous Lymphoma Task Force for EORTC, kindly consented to do an exhaustive review on cutaneous B-cell lymphoma, a topic in which knowledge and expertise is wanting since the number of cases from our country is small yet significant. We have also tried to put up strategies on the management of MF with a simple algorithm, issues with the treatment options, and a basic risk-based stratification. We have a non-MF series of CTCLs from Mexico by Dr. Yann Charli-Joseph *et al*., where the environment and skin colors are similar to that of India.

Finally, while we have made giant strides in diagnostics, we do have limited centers that have facilities for immunohistochemistry, T-cell receptor gene rearrangement studies for clonality, positron emission tomography-computed tomography scan, or total skin electron beam therapy when necessary for selected patients. We are in the process of creating a database for the same so that patients can be referred as and when needed. Since data are small and centers are sparse, we need a national registry to find more about the epidemiology, risks, and results of therapy in India. The biggest hurdle in the absence of epidemiological data is making the latest drugs in the management of lymphomas available to our patients. We do not have drugs such as bexarotene, pralatrexate, vorinostat, romidepsin, or alemtuzumab which are gradually becoming the standards of first-line management for advanced stage disease across the world. Creation of a registry for collection of national data is imperative, and referral centers need to be specifically identified for the benefit of clinicians and patients for the best possible treatment. Our clinical suspicion for lymphomas is higher than before leading to a rise in incidence or better disease identification, but our management strategies in the present day still remain limited. Liaising with our colleagues across the world with greater experience has helped us garner knowledge and improve our approach. One can only hope that, with a persistent interest from focused clinicians and patients, we will have better strategies and a larger armamentarium of therapeutic options for these conditions. I wish you all a pleasant and informative read in this novel symposium from Team IJD, with special thanks to Dr. Koushik Lahiri, Editor, who conceptualized this.
